News & Updates
Filter by Specialty:
Relugolix combo improves uterine fibroid symptoms regardless of fibroid location
Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.
Relugolix combo improves uterine fibroid symptoms regardless of fibroid location
17 May 2022Beta-blockers reduce mortality risk in older patients with HFrEF
Use of beta-blockers results in a lower risk of all-cause mortality, but not of heart failure (HF) readmission, in older patients with HR with reduced ejection fraction (HFrEF), reports a recent study. Results are similar between patients admitted and not admitted from nursing homes.
Beta-blockers reduce mortality risk in older patients with HFrEF
16 May 2022COVID-19 vaccine hesitancy persists in pregnant women despite recommendations
Acceptance rates of COVID-19 vaccines have remained unchanged among unvaccinated pregnant women following national recommendations, with nearly one-third of patients seeing the vaccine as something harmful to their pregnancy, according to a study.
COVID-19 vaccine hesitancy persists in pregnant women despite recommendations
16 May 2022LDL-C test after ASCVD event improves statin adherence, intensification
Low-density lipoprotein cholesterol (LDL-C) testing appears to improve statin adherence and management in patients with a history of atherosclerotic cardiovascular disease (ASCVD), suggests a recent study.
LDL-C test after ASCVD event improves statin adherence, intensification
16 May 2022Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis
Oral tebipenem pivoxil hydrobromide appears to be as good as intravenous ertapenem in the treatment of patients with complicated urinary tract infection (UTI) and acute pyelonephritis, with the two having a similar safety profile, according to data from a phase III study.
Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis
16 May 2022Long-term aspirin use lowers HCC risk in chronic HBV patients
Use of aspirin in the long term appears to markedly reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV), a study has shown.
Long-term aspirin use lowers HCC risk in chronic HBV patients
14 May 2022No apparent link between COVID-19 vax and cerebrovascular outcomes
Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.